Mini review on emerging methods of preparation of liposome and its application as Liposome drug delivery systems

<p>Liposomes, sphere-shaped vesicles consisting of one or more phospholipid bilayers, were fi rst</p><p>described in the mid-60s. Nowadays, they are a very useful reproduction, reagent, and device in various</p><p>scientifi c disciplines, including medicine, chemistry,...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Hoofdauteurs: Ateeq Rahman (Auteur), Veikko Uahengo (Auteur), Daniel Likius (Auteur)
Formaat: Boek
Gepubliceerd in: Open Journal of Pharmacology and Pharmacotherapeutics - Peertechz Publications, 2018-10-26.
Onderwerpen:
Online toegang:Connect to this object online.
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
Omschrijving
Samenvatting:<p>Liposomes, sphere-shaped vesicles consisting of one or more phospholipid bilayers, were fi rst</p><p>described in the mid-60s. Nowadays, they are a very useful reproduction, reagent, and device in various</p><p>scientifi c disciplines, including medicine, chemistry, biochemistry, colloid science, biology, physics,</p><p>biophysics, mathematics and theoretical. After the initial discoveries liposomes have made their way to</p><p>the market. Among numerous brilliant new drug delivery systems developed, liposomes characterize an</p><p>advanced technology to deliver active molecules to the site of action, and at present, several formulations</p><p>are in clinical use. Research on liposome technology has progressed from conventional vesicles to</p><p>'second-generation liposomes', in which long-circulating liposomes are obtained by modulating the lipid</p><p>composition, size, and charge of the vesicle. Liposomes with modifi ed surfaces have also been developed</p><p>using several molecules, such as glycolipids or sialic acid. This paper mini review summarizes exclusively</p><p>Nano-lipids, its applications in medicine scalable techniques in treating dreadful diseases cancer, AIDS,</p><p>paralysis etcand focuses on strengths, respectively, limitations in respect to industrial applicability and</p><p>regulatory requirements concerning liposomal drug formulations based on FDA and EMEA documents.</p>
DOI:10.17352/ojpp.000007